ORI Capital
Overview
ORI Capital is a venture capital firm founded in 2015. Our Funds invest in innovative early-stage biotech companies globally, in the areas of diagnostics, drug delivery, and therapeutics focused on the disease areas with the highest mortality rates: cancer, cardiovascular and neurodegenerative diseases .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| CG Oncology | Nov 2022 | Series E | Lead |
| Enable Injections | Oct 2018 | Series B | Co-investor |
| Pillar Biosciences | May 2020 | Series C | Lead |
| AffyImmune Therapeutics | Oct 2021 | Series A | Lead |
| Ponce De Leon Health | Mar 2021 | Series B | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is ORI Capital based?
ORI Capital is headquartered in Hong Kong SAR.
When was ORI Capital founded?
ORI Capital was founded in 2015.
How many portfolio companies does ORI Capital have?
ORI Capital has 13 portfolio companies in Caplight's dataset.
What are some companies in ORI Capital's portfolio?
Portfolio companies visible on Caplight include CG Oncology, Enable Injections, Pillar Biosciences, AffyImmune Therapeutics, Ponce De Leon Health.
What was ORI Capital's most recent investment shown here?
ORI Capital's most recent investment in this portfolio sample was in CG Oncology in 2022.
What sectors does ORI Capital focus on?
ORI Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure, Consumer & Commerce.
What company stages does ORI Capital focus on?
ORI Capital typically invests at the Early stage.
What is ORI Capital's AUM?
ORI Capital's assets under management are estimated between $250.0M and $500.0M.